Trevi Therapeutics (TRVI) News Today $2.77 -0.23 (-7.67%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Promising Prospects for Trevi Therapeutics’ Haduvio in Addressing Unmet Needs in Refractory Chronic CoughNovember 18 at 11:55 PM | markets.businessinsider.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by BrokeragesNovember 18 at 2:45 AM | americanbankingnews.comRome’s Trevi Fountain unveils elevated walkway for tourists to get closer look during cleaningNovember 14, 2024 | msn.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by AnalystsShares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and two hNovember 13, 2024 | marketbeat.comWhat is Leerink Partnrs' Estimate for TRVI FY2024 Earnings?November 12, 2024 | americanbankingnews.comLeerink Partnrs Has Negative Outlook of TRVI FY2024 EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2024 earnings estimates for shares of Trevi Therapeutics in a report issued on Wednesday, November 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earNovember 11, 2024 | marketbeat.comRome's Trevi Fountain gets temporary catwalk as famous landmark undergoes a cleaningNovember 10, 2024 | msn.comTourists in Rome now have a walkway to visit the Trevi Fountain but can’t toss coinsNovember 10, 2024 | apnews.comTrevi Therapeutics: Buy Rating Driven by Promising Haduvio Potential and Key Study DevelopmentsNovember 9, 2024 | markets.businessinsider.comTrevi Therapeutics: Promising Pipeline and Strategic Developments Support Buy RatingNovember 9, 2024 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comTrevi Therapeutics: Buy Rating Affirmed Amid Promising Haduvio Prospects and Upcoming Data MilestonesNovember 8, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Trevi Therapeutics (TRVI)November 7, 2024 | markets.businessinsider.comTrevi Therapeutics Reports Q3 2024 Progress and FinancialsNovember 7, 2024 | markets.businessinsider.comTrevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...November 7, 2024 | finance.yahoo.comTrevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 6, 2024 | prnewswire.comRosalind Advisors Inc. Has $2.51 Million Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Rosalind Advisors Inc. reduced its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 46.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 750,000 sharesNovember 6, 2024 | marketbeat.comThe Trevi Fountain Now Features a Kiddie PoolNovember 4, 2024 | msn.comTrevi fountain maintenance: Tradition preserved with coin poolNovember 3, 2024 | msn.comPool at Rome’s Trevi Fountain for coin tossing as the monument is repairedNovember 2, 2024 | apnews.comTourists toss coins over makeshift pool as Rome’s Trevi Fountain undergoes maintenanceNovember 1, 2024 | msn.comTrevi Therapeutics (TRVI) Set to Announce Quarterly Earnings on WednesdayTrevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comTrevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024October 30, 2024 | prnewswire.comInside A Clothing Store In Rome Are The Best Hidden Views Of The Trevi FountainOctober 25, 2024 | msn.comTrevi Therapeutics Positioned for Growth with Advancements in Chronic Cough Treatment and Undervalued Market PotentialOctober 22, 2024 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Trevi Therapeutics in a research note on Tuesday.October 22, 2024 | marketbeat.comStifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025October 22, 2024 | markets.businessinsider.comTrevi Therapeutics completes enrollment for Phase 2a RIVER trialOctober 22, 2024 | markets.businessinsider.comTrevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic CoughOctober 21, 2024 | prnewswire.comGloria Trevi & Maria Becerra Dazzle With Daring ‘Borracha’ Performance at 2024 Latin Music AwardsOctober 21, 2024 | msn.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from AnalystsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned an average recommendation of "Buy" from the nine analysts that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating toOctober 19, 2024 | marketbeat.comTrevi Therapeutics: Positive Outlook on Haduvio’s Potential Amid HAP Study InsightsOctober 17, 2024 | markets.businessinsider.comTrevi Therapeutics to Participate in Upcoming Commercial and Investor ConferencesOctober 15, 2024 | prnewswire.comRome Considers Entry Fee for Famed Trevi FountainOctober 12, 2024 | msn.comWhat happens to the millions of coins thrown into Rome’s Trevi Fountain?October 12, 2024 | apnews.comWhat happens to the millions of coins thrown into Rome's Trevi Fountain?October 11, 2024 | yahoo.comItaly: Changes for tourists in Rome: a walkway will be placed at the Trevi Fountain to regulate the number of visitorsOctober 11, 2024 | msn.comRome's Trevi Fountain Will Get a Much-Needed Cleaning—and a Controversial New Entry FeeOctober 11, 2024 | msn.comTrevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ...October 9, 2024 | finance.yahoo.comAccess to Rome’s Trevi fountain to be restricted in NovemberOctober 8, 2024 | msn.comVisitors To Get Rare View Of Rome's Trevi FountainOctober 8, 2024 | barrons.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Conmed (CNMD) and Revance Therapeutics (RVNC)October 4, 2024 | markets.businessinsider.comBuy Rating Affirmed on Trevi Therapeutics Amid Strong Clinical Trial Progress and Positive Upcoming MilestonesOctober 4, 2024 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday.October 4, 2024 | marketbeat.comTrevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development OfficerOctober 4, 2024 | finanznachrichten.deMaintaining Buy Rating on Trevi Therapeutics Amid Anticipated Clinical Milestones for HaduvioOctober 4, 2024 | markets.businessinsider.comTrevi Therapeutics Provides Update on Haduvio's Clinical Development ProgramOctober 3, 2024 | prnewswire.comTrevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development OfficerOctober 1, 2024 | stockhouse.comTrevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.September 30, 2024 | prnewswire.comTrevi Warrior Women Walk taking place next weekendSeptember 28, 2024 | msn.com Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. TRVI Media Mentions By Week TRVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼0.190.45▲Average Medical News Sentiment TRVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼23▲TRVI Articles Average Week Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VNDA News VYNE News CARA News NUVB News ETNB News TYRA News RAPP News RLAY News EOLS News PLRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRVI Stock Alerts